Interferon alpha-2a treatment for refractory Behcet uveitis in Korean patients

Ji Hwan Lee, Christopher Seungkyu Lee, Sungchul Lee

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: To evaluate therapeutic outcomes of interferon alpha-2a (IFNα2a) treatment in patients with Behcet's disease who were refractory to immunosuppressive agents. Methods: This retrospective case series reviewed the medical records of 5 patients with refractory Behcet uveitis from January 2011 to February 2017. IFNα2a was administered at a dose of 3 million IU 3 times per week. Clinical response, relapse rate, and change of visual acuity were evaluated. Results: The mean age of patients was 39.60 ± 9.21 years, and the median treatment duration was 6 months. Four of the 5 patients (80%) presented with responses to IFNα2a without any uveitis attack during the treatment period. The mean number of uveitis attacks/year per patient during the treatment was 0.40 ± 0.89. The mean log of the Minimum Angle of Resolution visual acuity improved from 1.44 ± 0.38 at baseline to 1.02 ± 0.58 at the final follow up. Conclusions: IFNα2a is an effective therapy for Behcet uveitis refractory to conventional immunosuppressants in Korean patients.

Original languageEnglish
Article number52
JournalBMC Ophthalmology
Volume18
Issue number1
DOIs
Publication statusPublished - 2018 Feb 20

Fingerprint

Uveitis
Immunosuppressive Agents
Visual Acuity
Therapeutics
Behcet Syndrome
Medical Records
interferon alfa-2a
Recurrence

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Lee, Ji Hwan ; Lee, Christopher Seungkyu ; Lee, Sungchul. / Interferon alpha-2a treatment for refractory Behcet uveitis in Korean patients. In: BMC Ophthalmology. 2018 ; Vol. 18, No. 1.
@article{9d524fcf88ca416f917285c9faa312d5,
title = "Interferon alpha-2a treatment for refractory Behcet uveitis in Korean patients",
abstract = "Background: To evaluate therapeutic outcomes of interferon alpha-2a (IFNα2a) treatment in patients with Behcet's disease who were refractory to immunosuppressive agents. Methods: This retrospective case series reviewed the medical records of 5 patients with refractory Behcet uveitis from January 2011 to February 2017. IFNα2a was administered at a dose of 3 million IU 3 times per week. Clinical response, relapse rate, and change of visual acuity were evaluated. Results: The mean age of patients was 39.60 ± 9.21 years, and the median treatment duration was 6 months. Four of the 5 patients (80{\%}) presented with responses to IFNα2a without any uveitis attack during the treatment period. The mean number of uveitis attacks/year per patient during the treatment was 0.40 ± 0.89. The mean log of the Minimum Angle of Resolution visual acuity improved from 1.44 ± 0.38 at baseline to 1.02 ± 0.58 at the final follow up. Conclusions: IFNα2a is an effective therapy for Behcet uveitis refractory to conventional immunosuppressants in Korean patients.",
author = "Lee, {Ji Hwan} and Lee, {Christopher Seungkyu} and Sungchul Lee",
year = "2018",
month = "2",
day = "20",
doi = "10.1186/s12886-018-0719-0",
language = "English",
volume = "18",
journal = "BMC Ophthalmology",
issn = "1471-2415",
publisher = "BioMed Central",
number = "1",

}

Interferon alpha-2a treatment for refractory Behcet uveitis in Korean patients. / Lee, Ji Hwan; Lee, Christopher Seungkyu; Lee, Sungchul.

In: BMC Ophthalmology, Vol. 18, No. 1, 52, 20.02.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Interferon alpha-2a treatment for refractory Behcet uveitis in Korean patients

AU - Lee, Ji Hwan

AU - Lee, Christopher Seungkyu

AU - Lee, Sungchul

PY - 2018/2/20

Y1 - 2018/2/20

N2 - Background: To evaluate therapeutic outcomes of interferon alpha-2a (IFNα2a) treatment in patients with Behcet's disease who were refractory to immunosuppressive agents. Methods: This retrospective case series reviewed the medical records of 5 patients with refractory Behcet uveitis from January 2011 to February 2017. IFNα2a was administered at a dose of 3 million IU 3 times per week. Clinical response, relapse rate, and change of visual acuity were evaluated. Results: The mean age of patients was 39.60 ± 9.21 years, and the median treatment duration was 6 months. Four of the 5 patients (80%) presented with responses to IFNα2a without any uveitis attack during the treatment period. The mean number of uveitis attacks/year per patient during the treatment was 0.40 ± 0.89. The mean log of the Minimum Angle of Resolution visual acuity improved from 1.44 ± 0.38 at baseline to 1.02 ± 0.58 at the final follow up. Conclusions: IFNα2a is an effective therapy for Behcet uveitis refractory to conventional immunosuppressants in Korean patients.

AB - Background: To evaluate therapeutic outcomes of interferon alpha-2a (IFNα2a) treatment in patients with Behcet's disease who were refractory to immunosuppressive agents. Methods: This retrospective case series reviewed the medical records of 5 patients with refractory Behcet uveitis from January 2011 to February 2017. IFNα2a was administered at a dose of 3 million IU 3 times per week. Clinical response, relapse rate, and change of visual acuity were evaluated. Results: The mean age of patients was 39.60 ± 9.21 years, and the median treatment duration was 6 months. Four of the 5 patients (80%) presented with responses to IFNα2a without any uveitis attack during the treatment period. The mean number of uveitis attacks/year per patient during the treatment was 0.40 ± 0.89. The mean log of the Minimum Angle of Resolution visual acuity improved from 1.44 ± 0.38 at baseline to 1.02 ± 0.58 at the final follow up. Conclusions: IFNα2a is an effective therapy for Behcet uveitis refractory to conventional immunosuppressants in Korean patients.

UR - http://www.scopus.com/inward/record.url?scp=85042591089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042591089&partnerID=8YFLogxK

U2 - 10.1186/s12886-018-0719-0

DO - 10.1186/s12886-018-0719-0

M3 - Article

VL - 18

JO - BMC Ophthalmology

JF - BMC Ophthalmology

SN - 1471-2415

IS - 1

M1 - 52

ER -